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REVIEW
Abstract: Fluvoxamine is a selective-serotonin reuptake inhibitor (SSRI) that has proved
effective in large double-blind, randomized, controlled trials involving patients with social
anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and panic disorder.
Improvements have also been demonstrated in patients with post-traumatic stress disorder, as
well as those with a range of obsessive-compulsive spectrum disorders including binge eating
disorder, bulimia nervosa, pathological gambling, and body dysmorphic disorder. Several well
controlled studies have confirmed the efficacy of fluvoxamine in children and adolescents
with OCD, SAD, and other anxiety disorders, and it was the first SSRI to be registered for the
treatment of OCD in children. Fluvoxamine is well tolerated. In common with other SSRIs,
the most frequently reported adverse event is nausea. Fluvoxamine does not cause sedation or
cognitive impairment and is associated with a low risk of sexual dysfunction, suicidality, and
withdrawal reactions. It is safe in overdose and has no significant effect on body weight or
cardiovascular parameters.
Keywords: fluvoxamine, anxiety disorders, obsessive-compulsive disorder, panic disorder,
post-traumatic stress disorder
Introduction
Fluvoxamine was the first of the selective serotonin reuptake inhibitors (SSRIs) that
remains in clinical use. Although originally developed as an antidepressant (Wilde et
al 1993) (an indication for which it is licensed in many countries, with the exception
of the United States), its most widespread application is in the treatment of anxiety
disorders, particularly obsessive-compulsive disorder (OCD). It was the first drug
licensed for use in adults, and subsequently for children as well, in OCD in the
United States. In recent years, there have been a number of studies of fluvoxamine in
other anxiety disorders, particularly in social anxiety disorder (SAD) and its eastern
equivalent taijin kyofusho (fluvoxamine was the first SSRI to be licensed in Japan).
There have been few recent reviews of fluvoxamine, and the majority of the older
reviews focus largely on its use in depression. Whilst fluvoxamine is undoubtedly
effective in depression, it is in the context of anxiety disorders that the drug is most
frequently encountered and where there is a lack of critical overviews of its utility.
This review examines the evidence for efficacy of fluvoxamine in OCD, SAD,
obsessive compulsive spectrum disorders, panic disorder, and post-traumatic stress
disorder (PTSD). Apart from the SSRIs, treatment options in these disorders have
major tolerability disadvantages, with benzodiazepines, tricyclic antidepressants, and
neuroleptics being the mainstay of treatment until the advent of the SSRIs.
Fluvoxamine has probably been better evaluated in a wider range of anxiety disorders
than any of the other SSRIs, and the publication of recent data in this area warrants
further review.
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Pharmacology
Fluvoxamine is a SSRI antidepressant. It potently inhibits
the reuptake of serotonin but has little effect on dopamine
and norepinephrine uptake systems. In addition, apart from
binding to σ1 receptors, it has a low affinity for neuro-
transmitter receptors (Leonard 1992; Hyttel 1993). The
affinity of fluvoxamine for σ1 receptors, which may be
involved in psychosis and aggression, is greater than that
seen with the other SSRIs (Narita et al 1996).
The anxiolytic activity of fluvoxamine has been
demonstrated in a number of animal models including the
ultrasonic rat pup vocalization test, anticipatory anxiety in
mice, and schedule-induced polydipsia in rats (Njung’e and
Handley 1991; Olivier et al 1993; Woods et al 1993).
Pharmacokinetics
The key pharmacokinetic properties of fluvoxamine are
summarized in Table 1. It is efficiently absorbed after oral
administration and its bioavailability is not affected by food.
Thereafter it undergoes widespread distribution, although
it has lower plasma protein binding than all other SSRIs
with the exception of citalopram. Extensive metabolism
occurs in the liver, with less than 4% of the dose being
excreted unchanged. None of the resulting metabolites have
psychotropic activity (Overmars et al 1983). Fluvoxamine
has an elimination half-life of approximately 15 hours after
a single dose, which increases by 30%–50% after multiple
dosing, thus making it suitable for once-daily dosing.
Excretion is via the urine. There is minimal excretion of
fluvoxamine in breast milk (Piontek et al 2001).
The pharmacokinetic profile of fluvoxamine is
unchanged in patients with renal impairment (van Harten
1995), but slower elimination in patients with hepatic
impairment may necessitate an initial dose reduction (van
Harten et al 1993). Age has little impact (de Vries et al 1992),
although slow titration is advised in elderly patients and the
recommended maximum dose for children is 200 mg/day.
In contrast to a number of other SSRIs, fluvoxamine is
only a weak inhibitor of cytochrome P450 (CYP) 2D6 and
is therefore unlikely to result in interactions when used in
combination with drugs that are metabolized by this
isoenzyme, eg, many antipsychotics (DeVane 1998).
Fluvoxamine is, however, a potent inhibitor of CYP1A2 and
a moderate inhibitor or CYP3A4 and CYP2C19, and may
prolong the elimination of agents metabolized by these
isoenzymes, eg, warfarin, theophylline, and some
benzodiazepines (DeVane 1998). There are no interactions
between fluvoxamine and alcohol (van Harten et al 1992),
lithium (Milijkovic et al 1997), or digoxin (Ochs et al 1989).
Clinical studies
Social anxiety disorder
SAD is the most common of the anxiety disorders, after
specific phobia, with a lifetime prevalence of at least 10%
(Kessler et al 1994; Weiller et al 1996). It is characterized
by a fear of embarrassment in social or performance
situations, and occurs in either the generalized form, which
is associated with a fear of many situations including, for
example, speaking, eating, writing in front of others, or
socializing in a group; or the nongeneralized form, where
the fear occurs in just one or two situations. The symptoms
can be severe, particularly in the generalized form, and lead
to significant impairment in education, work, social, and
family situations. Because onset is usually before or during
adolescence, patients can suffer for many years, and a high
risk of comorbidity with other psychiatric disorders
contributes to further disability.
A number of randomized, double-blind, placebo-
controlled studies have confirmed the efficacy of
fluvoxamine in improving the symptoms of SAD, as well
as reducing the disruption it causes in everyday life (Table 2)
(van Vliet et al 1994; Stein et al 1999, 2003; Davidson et al
2004; Westenberg et al 2004). Good evidence also exists
for the efficacy of paroxetine and sertraline (MacQueen et
al 2001; Wagstaff et al 2002), although fluoxetine showed
no significant difference from placebo in the only reported
double-blind study (Kobak et al 2002).
Fluvoxamine was the first SSRI to be evaluated in a
randomized, controlled trial for the treatment of SAD (van
Vliet et al 1994); the results from this small study showed a
Table 1 Pharmacokinetic properties of fluvoxamine
Oral absorption ≥ 94%
Cmax 31–87 mg/L
Tmax 2–8 hours
Time to reach steady-state ≈ 10 days
Absolute bioavailability ≈ 50%
AUC 927 µg/L˜hour
Vd 25 L/kg
Plasma protein binding ≈ 77%
t½β 15 hours after a single dose
Route of metabolism Hepatic oxidation
Route of excretion Urine
Data adapted from van Harten (1995).
Abbreviations: Cmax, maximum plasma concentration; Tmax, time to maximum
plasma concentration; AUC, area under the plasma concentration-time curve; Vd,
volume of distribution; t½β, terminal elimination half-life.Neuropsychiatric Disease and Treatment 2005:1(4) 291
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significantly greater improvement with fluvoxamine than
with placebo on the Liebowitz Social Anxiety Scale (LSAS),
Hamilton Anxiety Scale, and the 90-item Symptom
Checklist. In a larger study involving 86 patients who had
been suffering from SAD for an average of around 25 years,
fluvoxamine was significantly superior to placebo on the
LSAS, Brief Social Phobia Scale, Social Phobia Inventory,
and the Clinical Global Impression (CGI) response rate
(Stein et al 1999). Two subsequent studies, each involving
more than 250 patients diagnosed specifically with the
generalized form of SAD, confirmed that the controlled
release formulation of fluvoxamine (100–300 mg/day) was
significantly more effective than placebo on the LSAS, CGI
severity scale, and the Sheehan Disability Scale (SDS)
(Davidson et al 2004; Westenberg et al 2004). Interestingly,
fluvoxamine has also shown some efficacy in patients with
taijin kyofusho, a disorder thought to be a form of SAD
unique to Eastern cultures that is centred on a fear of
embarrassing or offending other people (Matsunaga et al
2001).
Because SAD is a chronic disorder, maintenance
treatment may be necessary. A 24-week, double-blind
extension study, conducted in 109 patients who had
experienced at least minimal improvement after 12 initial
weeks of treatment with fluvoxamine CR (100–300 mg/day)
or placebo (Westenberg et al 2004), showed that patients
treated with fluvoxamine continued to show greater
improvement than those given placebo, although the
magnitude of change was smaller in the extension than in
the acute phase (Stein et al 2003).
Fluvoxamine is also effective in children and adolescents
with SAD and other anxiety disorders and was the first SSRI
to be approved by the Food and Drug Administration for
use in children. In a randomized, double-blind study in 128
children and adolescents aged 6–17 years (> 70% aged ≤ 12
years) with SAD, separation anxiety disorder, or generalized
anxiety disorder, fluvoxamine (up to 300 mg/day) was
significantly more effective than placebo from week 3
onwards on the Pediatric Anxiety Rating Scale (Figure 1)
(Research Unit on Pediatric Psychopharmacology Anxiety
Study Group 2001). By the end of the 8-week study, the
mean score was < 10 in the fluvoxamine group, indicating
no more than mild anxiety, whilst it remained high in the
placebo group. The response rate (CGI improvement score
of < 4) was 76% with fluvoxamine and 29% with placebo
(p < 0.001). A 6-month open-label extension of this study
Table 2 Summary of randomized, double-blind, placebo controlled trials with fluvoxamine in social anxiety disorder
Percentage change in score
from baseline at end of study
CGI
severity Response
Study N Duration Regimens LSAS score SDS rate
van Vliet et al 1994 28 12 weeks FLV 150 mg/day –46% (anxiety)*** 46%a
–37% (avoidance)
Placebo –14% (anxiety) 7%
–20% (avoidance)
Stein et al 1999 86 12 weeks FLV 50–300 mg/day –28%** –35% (work) 43%b*
–25% (social)
–28% (family)
Placebo –9% +8% (work) 23%
0% (social)
+22% (family)
Stein et al 2003 109 24 weeks FLV CR 100–300 mg/day –60% –52%** –68%* 80%b
Placebo –51% –40% –54% 74%
Davidson et al 2004 279 12 weeks FLV CR 100–300 mg/day –30%** –22%*** –34%* 34%b***
Placebo –15% –11% –20% 17%
Westenberg et al 2004 294 12 weeks FLV CR 100–300 mg/day –37%
* –31%
* –41%
* 48%
b
Placebo –28% –21% –32% 44%
Abbreviations: FLV, fluvoxamine; CR, controlled-release; LSAS, Liebowitz Social Anxiety Scale; SDS, Sheehan Disability Scale; CGI, Clinical Global Impression severity
score.
a Based on LSAS.
b Based on CGI improvement.
*p < 0.05 vs placebo; **p < 0.01 vs placebo; ***p < 0.001 vs placebo.Neuropsychiatric Disease and Treatment 2005:1(4) 292
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showed that anxiety symptoms remained low in 94% of
patients who initially responded to fluvoxamine (Walkup
et al 2002). Amongst the 48 initial placebo nonresponders,
56% had a clinically significant improvement in anxiety
when switched to fluvoxamine; 71% of the 14 initial
fluvoxamine nonresponders also showed a significant
improvement when switched to fluoxetine.
Obsessive-compulsive disorder
OCD is characterized by recurrent or persistent obsessions
(thoughts) and compulsions (behaviors) that cause marked
distress and significantly interfere with everyday
functioning. It has a lifetime prevalence of 2%–5% (Karno
et al 1988) and a high degree of comorbidity.
The efficacy of fluvoxamine in the management of OCD
has been confirmed in a number of randomized, double-
blind, controlled studies, and it was the first SSRI to be
registered for this indication. Placebo-controlled studies
conducted over 6–12 weeks have consistently shown a sig-
nificantly better response to fluvoxamine (100–300 mg/day)
than to placebo as assessed by the Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS), National Institute of Mental
Health Obsessive-Compulsive (NIMH-OC) scale, and the
CGI scales (Perse et al 1987; Goodman et al 1989, 1996;
Jenike et al 1990; Greist et al 1995; Hollander et al 2003).
There is evidence from two placebo-controlled studies to
indicate that fluvoxamine significantly augments the efficacy
of behavior therapy (Cottraux et al 1993; Hohagen et al 1998).
The majority of double-blind, active treatment-controlled
studies have been conducted with the tricyclic antidepressant
Table 3 Summary of randomized, double-blind, active controlled trials with fluvoxamine in obsessive-compulsive disorder
Percentage change in score
from baseline at end of study
CGI
severity Response
Study N Duration Regimens Y-BOCS NIMH-OC score rate
Versus CMI
Freeman et al 1994 64 10 weeks FLV 150–250 mg/day –68% –73% 59%
a
CMI 150–250 mg/day –69% –73% 53%
Koran et al 1996 73 10 weeks FLV 100–300 mg/kg –30% 56%b
CMI 100–250 mg/kg –30% 54%
Milanfranchi et al 1997 25 9 weeks FLV 300 mg/kg –38% 85%a
CMI 300 mg/kg –40% 83%
Mundo et al 2000 128 10 weeks FLV 150–300 mg/kg –46% –40% –32% 60%a,b
CMI 150–300 mg/kg –50% –40% –33% 67%
Mundo et al 2001 217 10 weeks FLV 150–300 mg/day –46% –40% –32% 62%
b
CMI 150–300 mg/kg –47% –39% –33% 65%
Versus DMI
Goodman et al 1990 40 8 weeks FLV 100–300 mg/kg –29%* 52%a*
DMI 100–300 mg/kg –1% 11%
Abbreviations: FLV, fluvoxamine; CMI, clomipramine; DMI, desipramine; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale; NIMH-OC, National Institute of Mental
Health Obsessive-Compulsive scale; CGI, Clinical Global Impression severity score.
a Based on CGI improvement.
b Based on Y-BOCS.
*p ≤ 0.05 vs comparator.
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Figure 1 Mean Pediatric Anxiety Rating Scale score in children and adolescents
with SAD (separation anxiety disorder) or generalized anxiety disorder treated
with fluvoxamine or placebo. Source: Research Unit on Pediatric
Psychopharmacology Anxiety Study Group. 2001. Fluvoxamine for the treatment
of anxiety disorders in children and adolescents. N Engl J Med, 344:1279–85.
Copyright © 2001. Reproduced with permission from Massachusetts Medical
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clomipramine, a serotonin reuptake inhibitor (Table 3)
(Freeman et al 1994; Koran et al 1996; Milanfranchi et al
1997; Mundo et al 2000, 2001). These studies all showed
that fluvoxamine and clomipramine are equally effective
for the treatment of OCD, although fluvoxamine was
generally better tolerated. One study compared the
effects of fluvoxamine with the tricyclic antidepressant
desipramine which, in contrast to clomipramine, is a
noradrenaline reuptake inhibitor (Table 3) (Goodman et al
1990). The response rate and the percentage reduction
in the Y-BOCS score at the end of the study were both sig-
nificantly greater with fluvoxamine than with desipramine
(p ≤ 0.05).
Long-term maintenance treatment with fluvoxamine
appears to reduce the risk of relapse, and there is some
indication that lower dosages may be effective, although
only small studies have been conducted to date (Ravizza et
al 1996; Mundo et al 1997).
As with other anxiety disorders, fluvoxamine has proved
effective in children and adolescents with OCD. A 10-week,
double-blind, placebo-controlled study in 120 children
and adolescents (approximately 50% were aged 8–12 years
and 50% aged 13–17 years) showed that fluvoxamine
(50–200 mg/day) was significantly superior to placebo on
the Children’s Yale-Brown Obsessive Compulsive Scale
(CY-BOCS) from week 1 onwards (p < 0.05) (Figure 2)
(Riddle et al 2001). Such an early response is not generally
observed in studies in adult patients. Statistically significant
differences between fluvoxamine and placebo were also seen
on the NIMH-OC and CGI scales and a response (≥ 25%
reduction in CY-BOCS total score) was achieved in 42% of
fluvoxamine patients and 26% of placebo patients. In a 1-
year open extension phase involving 98 patients,
continuation of fluvoxamine (200 mg/day) resulted in further
small beneficial effects, whilst patients switched from
placebo to fluvoxamine experienced a marked improvement
in CY-BOCS score (Walkup et al 1999).
Obsessive-compulsive spectrum
disorders
Obsessive-compulsive spectrum disorders consist of a group
of conditions, each of which has distinct diagnostic criteria,
which share certain features with OCD (eg, demographics,
symptoms, neurobiology, and effective treatments)
(Hollander and Wong 1995). Fluvoxamine has proved
effective in a number of these disorders and is probably one
of the most widely studied SSRIs in this area, although many
of the studies had an open design and involved only small
numbers of patients. Randomized, double-blind, controlled
studies have, however, been conducted in patients with binge
eating disorder, bulimia nervosa, pathological gambling,
compulsive buying, and autism.
Binge eating disorder
Binge eating is one of the common eating disorders and is
characterized by recurrent episodes of uncontrolled over-
eating. Unlike patients with bulimia nervosa, no measures
are taken to avoid weight gain. In a randomized, double-
blind study in 83 patients, fluvoxamine (50–300 mg/day)
was significantly (p < 0.05) more effective than placebo
after 9 weeks in terms of rates of reduction in CGI severity
score, body mass index, and the frequency of binges, and
rate of increase in CGI improvement score and level of
response (Hudson et al 1998). The addition of fluvoxamine
(300 mg/day), but not fluoxetine (60 mg/day), has also been
reported to enhance the efficacy of cognitive behavioral
therapy in a 6-month randomized study involving 108
patients (Ricca et al 2001).
Bulimia nervosa
Patients with bulimia nervosa also experience compulsive
eating binges, but their fear of loss of control and consequent
weight gain leads them to use measures such as vomiting
and taking laxatives. Fluvoxamine (100–300 mg/day) proved
significantly (p < 0.05) more effective than placebo in
preventing relapse in a 12-week, randomized, double-blind
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Figure 2 Mean CY-BOCS total score in children and adolescents with OCD
treated with fluvoxamine or placebo. Source: Riddle MA, Reeve EA, Yaryura-
Tobias J, et al. 2001. Fluvoxamine for children and adolescents with obsessive-
compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child
Adolesc Psychiatry, 40:222–9. Reproduced with permission from Lippincott
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study in 72 patients who had already been successfully
treated with psychotherapy (Fichter et al 1996, 1997). An
earlier open study in 20 patients showed that fluvoxamine
(50–150 mg/day) significantly (p < 0.05) reduced various
aspects of bulimic behavior (Ayuso-Gutierrez et al 1994).
Pathological gambling
Pathological gambling is a chronic and progressive condition
that results in significant impairment in everyday living and
a high rate of suicide attempts. Following promising findings
with fluvoxamine (100–300 mg/day) in a single-blind
crossover study, in which a response was achieved in 7 out
of the 10 patients (Hollander et al 1998), a small (n = 10)
randomized, double-blind crossover study was conducted
by the same group (Hollander et al 2000). Fluvoxamine
(100–250 mg/day) treatment for 8 weeks resulted in a
significantly greater improvement in overall gambling
severity on the Pathological Gambling-CGI scale compared
with placebo (41% vs 17%; p < 0.005). Gambling urge and
behavior were also significantly improved with fluvoxamine
treatment.
Compulsive buying
A response (as assessed by the shopping version of the
Y-BOCS) to fluvoxamine (up to 300 mg/day) was reported
in 9 out of 10 patients enrolled in a 9-week open study;
patients were less preoccupied with shopping and reported
spending less money (Black et al 1997). A subsequent
9-week, randomized, double-blind study in 23 patients
reported a significantly (p < 0.05) greater improvement with
fluvoxamine (up to 300 mg/day) than with placebo on the
Maudsley Obsessive-compulsive Inventory (Black et al
2000). However, there were no other statistically significant
differences between the two treatment groups.
Autism
The efficacy of fluvoxamine (50–300 mg/day) in autistic
adults was demonstrated in a 12-week, randomized, double-
blind study involving 30 patients (McDougle et al 1996).
Significant (p < 0.05) benefits over placebo were seen in
repetitive thoughts and behaviors, maladaptive behavior, and
aggression and aspects of social relatedness, notably
language use. A response was seen in 53% of fluvoxamine-
treated patients compared with none in the placebo group
(p < 0.01). Autistic children have also shown a response to
fluvoxamine in an open study (Yokoyama et al 2002) and a
double-blind, crossover study (Fukuda et al 2001). The latter
involved 18 children and showed significant (p < 0.05)
improvements in a number of behaviors including eye
contact and language use.
Body dysmorphic disorder
Although no double-blind studies have been reported to date,
there are considerable data from noncomparative trials to
indicate that fluvoxamine is beneficial in patients with body
dysmorphic disorder (Hollander et al 1994; Perugi et al
1996; Phillips et al 1998, 2001). Scales used to assess the
efficacy of fluvoxamine include the Y-BOCS modified for
body dysmorphic behavior, the Brown Assessment of Beliefs
Scale, and the CGI. Psychogenic skin excoriation, which is
commonly seen in patients with body dysmorphic disorder,
has also been shown to respond to fluvoxamine (Arnold et
al 1999; O’Sullivan et al 1999).
Other disorders
Other disorders in which fluvoxamine has shown beneficial
effects include pervasive developmental disorders (Martin
et al 2003), trichotillomania (Stanley et al 1997), and
hypochondriasis (Fallon et al 2003).
Panic disorder
Patients with panic disorder suffer from recurrent panic
attacks characterized by a range of somatic and cognitive
symptoms including sweating, trembling, shortness of
breath, palpitations, and fear of dying or losing control. It
has a lifetime prevalence of around 3% (Kessler et al 1994),
and patients often suffer from comorbid agoraphobia or
depression.
Randomized, double-blind, placebo- and active-
controlled studies have shown that fluvoxamine is effective
in patients with panic disorder (with or without agora-
phobia), reducing both the number of panic attacks and the
level of anxiety. Three short-term, placebo-controlled studies
(one large-scale [n = 179 Asnis et al 2001] and two smaller
scale [n = 36 Hoehn-Saric et al 1993; and n = 46 Sandmann
et al 1998]) showed that fluvoxamine (up to 300 mg/day)
was significantly (p < 0.05) more effective than placebo in
reducing the number of panic attacks. In two studies (Hoehn-
Saric et al 1993; Asnis et al 2001), the frequency of full
panic attacks per week was reduced by 74%–100% with
fluvoxamine and 33%–66% with placebo (p < 0.05) at the
end of treatment, whilst the third study (Sandmann et al
1998) showed a significant difference only in the frequency
of limited symptom attacks (53% vs 31%; p < 0.05). Anxiety,
as assessed by the Clinical Anxiety Scale (CAS), was also
reduced to a significantly greater extent by fluvoxamine.Neuropsychiatric Disease and Treatment 2005:1(4) 295
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Four small, short-term studies have compared
fluvoxamine with other active pharmacotherapeutic
treatments. In two of these studies, fluvoxamine (up to
150 mg/day) was significantly (p < 0.05) more effective than
ritanserin and maprotiline, although neither are indicated
for the treatment of panic disorder (den Boer and Westenberg
1988, 1990). Fluvoxamine (up to 300 mg/day) proved
significantly (p < 0.01) more effective than imipramine (up
to 300 mg/day) in reducing the total number of panic attacks
in a placebo-controlled study involving 54 patients with
severe panic disorder (Bakish et al 1996). Anxiety was
improved to a similar extent in both groups. A lower dose
of fluvoxamine (150 mg/day) did not differ significantly
from brofaromine (150 mg/day) in reducing the frequency
of panic attacks, anxiety, and avoidance behavior in a
somewhat smaller study of 30 patients (van Vliet et al 1995).
Four randomized, placebo-controlled studies have
assessed the effects of fluvoxamine in comparison with, or
in combination with, various behavioral treatments.
Fluvoxamine (up to 300 mg/day) proved more effective than
cognitive therapy in 55 patients with moderate to severe
panic disorder (Black et al 1993). After 8 weeks, the
percentage of patients free of panic attacks was 73% in the
fluvoxamine group compared with 48% and 25% in the
cognitive therapy and placebo groups, respectively. The final
CAS score was significantly lower with fluvoxamine than
with cognitive therapy or placebo (p < 0.05). In a somewhat
larger (n = 149) 12-week study, a lower dose of fluvoxamine
(up to 150 mg/day) did not show any significant benefits
over cognitive therapy, although an additive effect was
observed when the two treatments were used together (Sharp
et al 1996). Fluvoxamine (up to 150 mg/day) also enhanced
the effects of exposure therapy in a 12-week study in 76
patients (de Beurs et al 1995). A 2-year follow-up showed
that the beneficial effects of fluvoxamine plus exposure
therapy were maintained and that these patients tended to
require less aftercare than those not treated with fluvoxamine
(de Beurs et al 1999).
Post-traumatic stress disorder
Patients with post-traumatic stress disorder (PTSD) re-
experience previous extreme trauma (eg, rape or combat)
in the form of persistent dreams and flashbacks and suffer
from hyperarousal and numbing symptoms. Only a minority
of patients who survive trauma go on to develop PTSD,
thus suggesting that it is not just a normal reaction.
Fluvoxamine has shown efficacy in both civilians and
war veterans with PTSD, although only small open,
noncomparative studies have been conducted to date. Four
studies involved veterans from either World War II (de Boer
et al 1992) or the Vietnam War (Marmar et al 1996; Neylan
et al 2001; Escalona et al 2002) treated with fluvoxamine
(100–300 mg/day) for between 10 and 14 weeks. Improve-
ments were seen in intrusion, avoidance, and hyperarousal
symptoms in all four studies, together with a reduction in
anxiety. In one study that focused particularly on sleep
disturbance, fluvoxamine improved all domains of
subjective sleep quality, the greatest effect being seen for
reduction of dreams linked to the traumatic experience
(Neylan et al 2001). Sleep maintenance insomnia and
troubled sleep also showed a large treatment response. A
substantial improvement in sleep quality was also noted in
the study involving World War II veterans (de Boer et al
1992).
Two studies have assessed fluvoxamine in civilians with
PTSD. In a 4-week study in 14 patients who had experienced
a variety of traumatic events (mainly traumatic bereavement
and childhood sexual trauma), fluvoxamine (50–300 mg/day)
significantly (p < 0.05) improved the symptoms of PTSD
on a range of efficacy scales, the mean reduction from
baseline ranging from 35% to 48% (Davidson et al 1998).
Autonomic reactivity (heart rate, blood pressure) to trauma
scripts fell significantly (p < 0.05) following 10 weeks of
fluvoxamine treatment (100–300 mg/day) in 16 PTSD
patients (Tucker et al 2000). Significant improvements were
also seen in PTSD symptom clusters and depression.
Tolerability and patient
acceptability
Fluvoxamine is generally well tolerated and has proved safe
in all age groups from children (Research Unit on Pediatric
Psychopharmacology Anxiety Study Group 2001; Riddle
et al 2001) to the elderly (Wagner et al 1996; Jaquenoud
and Kat 1997) and in patients with mild cardiovascular
disease or epilepsy (Harmant et al 1990; Präger et al 1991).
In common with other SSRIs, nausea is the most frequent
adverse event. A review of 66 postmarketing studies
conducted worldwide in 34 587 patients (mainly suffering
from depression) treated with fluvoxamine (50–300 mg/day;
modal dose 100 mg/day) for between 4 to 52 weeks showed
that nausea occurred in 15.7% of patients; all other adverse
events had an incidence of < 10% (Table 4). Prescription-
event monitoring of fluvoxamine in 10 401 patients also
showed nausea to be the only event seen in > 10% of patients
(Edwards et al 1994). A very low level of suicidality was
reported in these studies (Edwards et al 1994; Wagner et alNeuropsychiatric Disease and Treatment 2005:1(4) 296
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1994) and this was confirmed in global postmarketing
surveillance data obtained over 17 years in an estimated 28
million patients exposed to fluvoxamine (Buchberger and
Wagner 2002). Switch to mania, serotonin syndrome, and
convulsions are rarely reported and, although some patients
may experience withdrawal symptoms, they are generally
mild and resolve spontaneously. Fluvoxamine is relatively
safe in overdose, an important consideration in patients with
psychiatric disorders. In a review of 221 cases of overdose
(≤ 9 g), the acute toxicity that could be attributed to
fluvoxamine alone was rarely severe and cardiotoxicity was
rare (Garnier et al 1993).
Fluvoxamine does not significantly change body weight
(Harris and Ashford 1991) and has few cardiovascular or
anticholinergic effects (Präger et al 1991; Flett et al 1992;
Wagner et al 1994; Hochberg et al 1995). Studies have
shown negligible sedation or impairment in cognitive or
psychomotor function (Saletu et al 1983; Hindmarch 1995).
A meta-analysis of 73 double-blind, crossover, placebo- or
verum-controlled studies assessing the effects of drugs used
in the treatment of SAD on objective parameters of cognitive
and psychomotor performance in healthy volunteers showed
that only fluvoxamine and bupropion were entirely free of
impairment in any test (Hindmarch and Trick in press). A
total of 1949 individual psychometric tests were evaluated,
of which 428 (22%) showed impairment after drug
administration. Fluvoxamine does not appear to disrupt sleep
(Silvestri et al 2001) and has indeed shown beneficial effects
on sleep in patients with PTSD (Neylan et al 2001).
In contrast to many antidepressants, fluvoxamine has a
low incidence of sexual dysfunction. Prescription event
monitoring and postmarketing studies rarely report sexual
problems. However, in studies designed to specifically assess
sexual side effects, fluvoxamine appears to have less effect
than the other SSRIs on sexual function (Nemeroff et al
1995; Montejo et al 1996, 1997). A 6-week, double-blind
study in healthy men with premature ejaculation showed
that placebo and fluvoxamine had no effect on ejaculation
time whilst paroxetine, fluoxetine, and sertraline all
significantly increased ejaculation latency, the greatest effect
being seen with paroxetine (Figure 3) (Waldinger et al 1998).
Conclusions
Anxiety disorders are extremely common, highly disabling,
and associated with considerable comorbidity with
depression, substance abuse disorders, and other serious
psychiatric illnesses. This category of illness therefore
represents an important area of medical need. The well
known disadvantages of the benzodiazepines, tricyclic
antidepressants, and neuroleptics have resulted in the SSRIs,
with their relatively benign adverse event profile, becoming
first-line treatment for many anxiety disorders. Among the
SSRIs, fluvoxamine has been particularly well studied and
was the first to be approved in OCD. Importantly,
fluvoxamine has also been fully studied in children and
adolescents, since some anxiety disorders (OCD and SAD
in particular) have their onset in childhood.
The efficacy of fluvoxamine has been demonstrated by
double-blind, randomized, controlled studies in OCD, SAD,
and panic disorder. It lacks the common treatment-limiting
Table 4 Incidence of adverse events (≥ 2%) with fluvoxamine
in postmarketing studies (n = 34 587)
Incidence
Adverse event (%)
Nausea 15.7
Somnolence 6.4
Asthenia 5.1
Headache 4.8
Dry mouth 4.8
Insomnia 4.0
Dizziness 3.7
Abdominal pain 3.5
Vomiting 3.5
Dyspepsia 3.2
Constipation 3.2
Nervousness 3.2
Tremor 2.8
Diarrhea 2.4
Anorexia 2.2
Adapted from Wagner et al (1994).
Figure 3 Increase in intravaginal ejaculation latency time (IELT) after 6 weeks in
patients with premature ejaculation. Data adapted from Waldinger et al (1998).
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anticholinergic and cognitive side effects and cardiotoxicity
of the tricyclic antidepressants (heretofore clomipramine
was the mainstay of OCD treatment), and the cognitive
impairment and dependence susceptibility of the benzo-
diazepines that are used in a variety of other anxiety
disorders. It is also safe in overdose and is associated with a
low incidence of suicidality. Compared with the other SSRIs,
fluvoxamine has a generally similar tolerability profile,
dominated by usually mild and self-limiting gastrointestinal
complaints, but appears to cause less sexual side effects and
less cognitive disturbance. Unlike paroxetine, it does not
induce a significant withdrawal syndrome. Fluvoxamine can
therefore be considered a first-line treatment for adults and
children with a range of anxiety disorders.
As well as clinical trials, the safety and tolerability of
fluvoxamine has been established in extensive, published
postmarketing studies, prescription event monitoring, and
specific studies in patients with concomitant medical
problems such as cardiovascular disease and multi-
medicated elderly patients. The safety and tolerability of
fluvoxamine in real-world use has thus been widely studied.
Whilst the efficacy of fluvoxamine in a variety of anxiety
disorders is well established from randomized, clinical
studies, there is a relative lack of published large naturalistic
efficacy studies. However, there is now considerable clinical
experience with fluvoxamine and no reason to believe that
the efficacy of fluvoxamine under routine clinical conditions
would differ in any significant way from that observed in
clinical studies.
Overall, fluvoxamine is an important first-line therapy
in the treatment of OCD, SAD, and panic disorder. Its
tolerability profile is better than traditional treatments and
may offer some advantages over other SSRIs.
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